Palbocent 125 mg is identified on this website as a pharmaceutical product containing palbociclib 125 mg.
Product identity
| Product characteristic | Information |
|---|---|
| Product | Palbocent |
| Active ingredient | Palbociclib |
| Strength | 125 mg |
| Dosage form | Oral |
| Route | Oral, subject to product documentation |
| Drug class | CDK4/6 inhibitor |
| Therapeutic category | Antineoplastic |
| Reference product | IBRANCE |
| Reference-product developer | Pfizer |
| Specific manufacturer | Incepta Pharmaceuticals Ltd. |
| Marketing authorization holder | Incepta Pharmaceuticals Ltd. |
| Distributor | Incepta Pharmaceuticals Ltd. |
Pharmacologic identity
Palbociclib inhibits CDK4 and CDK6, enzymes involved in cell-cycle regulation.
Therapeutic context
Palbociclib is used in selected breast cancer treatment settings and is not appropriate for every breast cancer subtype.
Current U.S. labeling includes specific HR-positive/HER2-negative treatment settings and the newer HR-positive/HER2-positive maintenance indication approved in June 2026.
Reference product
IBRANCE is the established reference product associated with palbociclib. Pfizer received initial U.S. FDA approval in 2015.
Product relationship
Palbocent should not automatically be described as IBRANCE. The specific relationship between Palbocent and the reference product is:
Safety
Important palbociclib risks include neutropenia, infection, ILD/pneumonitis and embryo-fetal toxicity.
Product verification
Before use, the actual package should be checked for product identity, strength, dosage form, manufacturer, batch information and expiry date.